BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Energenesis Biomedical Co.\, Ltd. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Energenesis Biomedical Co.\, Ltd.
 's drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07647614-1637@assetmemo.bio
DTSTAMP:20261121T005930Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:ENERGI-F705: Phase 2 readout est. (NCT07647614)
DESCRIPTION:ENERGI-F705\, phase 2\, Parkinson's Disease.\nStudy: A Study to
  Evaluate the Efficacy and Safety of ENERGI-F705 Tablets for Parkinson's D
 isease\nEstimated primary completion: 1 January 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/energi-f705#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07647614
URL:https://assetmemo.bio/drug/energi-f705#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
